Document is current
Any future updates will be listed below
-
Authors
Wise-Draper, Trisha
Gulati, Shuchi
Takiar, Vinita
Palackdharry, Sarah
Worden, Francis
Old, Matthew
Kaczmar, John
Dunlap, Neal
Hinrichs, Benjamin
Bell, Diana
Patil, Yash
Riaz, Muhammad Kashif
Weatherford, Layne
Hamilton, Aubrey
Lanverman, Sheena
Mierzwa, Michelle
Casper, Keith
Mark, Jonathan
Tang, Alice
Zender, Chad
Gillenwater, Ann
Medvedovich, Mario
Jack Lee, J
Jandarov, Roman
Gillison, Maura
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02641093 at ClinicalTrials.govDocuments that mention this clinical trial
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
PD1 blockade enhances K<sup>+</sup> channel activity, Ca<sup>2+</sup> signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer
https://doi.org/10.1136/jitc-2020-000844
809 Phase 2 trial of neoadjuvant and adjuvant PD-1 checkpoint blockade in local-regionally advanced, resectable HNSCC indicates pathological response is associated with high disease-free survival
https://doi.org/10.1136/jitc-2020-sitc2020.0809
- License Information
